CTO

¿Fin de la discusión sobre el impacto del marcapaso post TAVI?

MIDAS Strategy: Minimizing Implantat Depth According to Membranous Septum

Permanent pacemaker implantation following transcatheter aortic valve replacement (TAVR) continues to be one of the most frequent complications. Even though its real impact on prognosis continues to be controversial, its impact on healthcare cost is out of the question, in addition to being uncomfortable for patients.  This study, soon to be published in J Am...

Simposio SOLACI en el Congreso SOCHICAR 2019

SOLACI Symposium at SOCHICAR 2019

The Latin American Society of Interventional Cardiology is proud to present together with the Chilean Society of Cardiology (SOCHICAR) a joint symposium to take place during SOCHICAR 2019 on November 28 thru 30 at the Hotel del Mar in Viña del Mar (Chile). The session will be entirely dedicated to the analysis of “Controversies in the Management of...

Sangrados mayores en pacientes con AAS más rivaroxabán

Major Bleeding in Patients with Aspirin Plus Rivaroxaban

The combination of coronary artery disease or peripheral vascular disease and a reason for anticoagulation, such as atrial fibrillation, results in many patients who receive antiplatelet therapy with aspirin plus anticoagulation with rivaroxaban, for example. It is a well-known fact that this combination (aspirin 100 mg per day plus rivaroxaban 2.5 mg twice per day) reduces cardiovascular...

Sangrados mayores en pacientes con AAS más rivaroxabán

Major Bleeding in Patients with Aspirin Plus Rivaroxaban

The combination of coronary artery disease or peripheral vascular disease and a reason for anticoagulation, such as atrial fibrillation, results in many patients who receive antiplatelet therapy with aspirin plus anticoagulation with rivaroxaban, for example. It is a well-known fact that this combination (aspirin 100 mg per day plus rivaroxaban 2.5 mg twice per day) reduces cardiovascular...

Comunicado | Suspensión de las XL Jornadas SOLACI en Manta, Ecuador

SOLACI Statement | XL SOLACI Sessions in Manta, Ecuador, Suspended

Due to the difficult situation in Ecuador, the Latin American Society of Interventional Cardiology is sorry to inform that the XL Regional Sessions (which were to be conducted in Manta City, Ecuador, on October 11th and 12th, 2019) have been suspended. The event has been rescheduled for March 6th and 7th, 2020, at the same location....

Highlights TCT 2019

TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Courtesy of Dr. Carlos Fava. Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3 years. However, beyond such term, we had no valid information. Researchers analyzed the 5-year follow-up results for the...

Highlights TCT 2019

TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses

Courtesy of SBHCI. The aim of this work was to assess the contemporary outcomes of mitral valve-in-valve using Sapien 3 prostheses, see the differences between trasapical and transseptal access, and establish 1-year mortality predictors. Researchers analyzed retrospectively the data from the Society of Thoracic Surgeons [STS]/American College of Cardiology TVT Registry, which included 1576 patients who had...

Highlights TCT 2019

TCT 2019 | EVOLVE Short DAPT: Only 3-month DATP in High Risk Bleeding

Courtesy of the SBHCI. This study used the thin strut everolimus eluting stent with ultrathin abluminal bioresorbable polymer coating chromium platinum stent, basically the Synergy stent. Drug release and polymer degradation within four months facilitate endothelization and would allow a shorter DAPT. Presented during the scientific sessions of TCT 2019, this study included 2009 high...

Highlights TCT 2019

TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS

Courtesy of SBHCI. The safety and efficacy of antithrombotic and antiplatelet treatments in patients with atrial fibrillation admitted with acute coronary syndrome (who receive medical treatment or angioplasty) may vary from that in patients undergoing elective treatment. At 14 days from elective angioplasty or hospitalization due to acute coronary syndrome, patients were randomized in a 2×2...

Top